Thursday, June 19, 2025 6/19/2025

IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes

Award Number: R44AI136201
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes - SUMMARY The broad, long-term goal of this project is to develop a pritelivir intravaginal ring (IVR) for the treatment and pre-exposure prophylaxis of genital herpes, a common problem that affects more than 30 million Americans. Recurrences are common and may be painful, and infection is life-long, yet few treatment options exist. Pritelivir is a promising α-helicase inhibitor that has been proven superior to existing therapies in Phase 2 clinical trials, but whose clinical development as a systemic therapy has been slowed due to observed unexplained systemic toxicity in primates. Therefore, pritelivir-based local therapy is of special interest. We have developed a platform technology for the sustained release of antivirals. This technology has successfully led to the development and commercialization of a ganciclovir intraocular implant – Vitrasert®, for the treatment of AIDS-related cytomegalovirus retinitis. This platform has been adapted to IVRs and through its use we have successfully delivered other antiviral agents at therapeutic levels in preclinical and clinical trials. We seek to utilize this platform to develop a sustained release IVR formulation for pritelivir. We achieved the specific aims of our Phase I and II SBIR, which were to: formulate pritelivir-releasing IVRs; test their in vitro release and in vivo safety and pharmacokinetics (PK) in animals; perform chemistry, manufacturing, and controls (CMC) activities; develop clinical documents; and submit an Investigational New Drug (IND) application to the FDA. The successful completion of this Phase I/II SBIR work has enabled us to identify an IVR dose for the further development of a drug product that is safe and demonstrates sustained release for 28 days and at clinically relevant levels. The IND has been placed on Clinical Hold, pending completion of additional nonclinical pharmacology and toxicology studies, CMC testing, and device evaluation. We, therefore, propose in Phase IIB to accomplish the FDA-guided nonclinical activities required to enable an IND allowance. The proposed Specific Aims of this Phase IIB SBIR are to: develop GMP-grade manufacturing capacity for the drug substance; conduct pharmacology and toxicology studies in rodents and nonrodents; manufacture GMP- grade drug product; perform device testing in accordance with CRDH’s comments; and re-submit an IND application to the FDA. The milestone for the successful completion of the proposed Phase IIB work is the approval of an IND to perform a first-in-human exploratory clinical trial for a pritelivir IVR. In future work, we will test the lead formulation for safety and PK in female volunteers in accordance with our FDA-approved clinical protocol. The team of investigators are experts in drug development, synthetic chemistry, pharmacokinetics, and clinical infectious disease, and have experience collaborating with large pharmaceutical companies to enable New Drug Approvals (NDAs) of novel drug delivery systems. This project could lead rapidly to the development of an improved treatment and prophylaxis for genital herpes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $1,025,000 )
2024	2024	AURITEC PHARMACEUTICALS, INC.	2285 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	5	7/24/2024	NON-COMPETING CONTINUATION	$1,025,000
														Subtotal = $1,025,000

Issue Date FY: 2023 ( Subtotal = $1,025,000 )
2023	2023	AURITEC PHARMACEUTICALS, INC.	2285 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Allergy and Infectious Diseases Research	001	4	9/14/2023	COMPETING CONTINUATION	$1,025,000
2023	2020	AURITEC PHARMACEUTICALS, INC.	2285 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	10/17/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,025,000

Issue Date FY: 2020 ( Subtotal = $1,000,000 )
2020	2020	AURITEC PHARMACEUTICALS, INC.	2285 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	3	2/28/2020	NON-COMPETING CONTINUATION	$1,000,000
														Subtotal = $1,000,000

Issue Date FY: 2019 ( Subtotal = $860,561 )
2019	2019	AURITEC PHARMACEUTICALS INC	3200 SANTA MONICA BLVD STE 201	SANTA MONICA	CA	90404	LOS ANGELES	USA	Allergy and Infectious Diseases Research	000	2	4/3/2019	COMPETING CONTINUATION	$860,561
														Subtotal = $860,561

Grand Total All Awards = $3,910,561

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes

Award Number: R44AI136201

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer